212 related articles for article (PubMed ID: 19337948)
1. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.
Hoving JL; Bartelds GM; Sluiter JK; Sadiraj K; Groot I; Lems WF; Dijkmans BA; Wijbrandts CA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
Scand J Rheumatol; 2009; 38(4):246-50. PubMed ID: 19337948
[TBL] [Abstract][Full Text] [Related]
2. Work ability: a new outcome measure in rheumatoid arthritis?
Raterman HG; Hoving JL; Nurmohamed MT; Herenius MM; Sluiter JK; Lems WF; Tak PP; Dijkmans BA; Twisk J; Frings-Dresen MH; Voskuyl AE
Scand J Rheumatol; 2010 Mar; 39(2):127-31. PubMed ID: 20059369
[TBL] [Abstract][Full Text] [Related]
3. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab.
Herenius MM; Hoving JL; Sluiter JK; Raterman HG; Lems WF; Dijkmans BA; Tak PP; Nurmohamed MT; Voskuyl AE; Frings-Dresen MH
J Occup Environ Med; 2010 Jun; 52(6):618-21. PubMed ID: 20523240
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
5. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
6. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
7. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).
Augustsson J; Neovius M; Cullinane-Carli C; Eksborg S; van Vollenhoven RF
Ann Rheum Dis; 2010 Jan; 69(1):126-31. PubMed ID: 19470527
[TBL] [Abstract][Full Text] [Related]
8. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
Halpern MT; Cifaldi MA; Kvien TK
Ann Rheum Dis; 2009 Jun; 68(6):930-7. PubMed ID: 18829616
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
Vanier A; Mariette X; Tubach F; Fautrel B;
Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
13. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA.
Kimel M; Cifaldi M; Chen N; Revicki D
J Rheumatol; 2008 Feb; 35(2):206-15. PubMed ID: 18085743
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis.
Walsh CA; Minnock P; Slattery C; Kennedy N; Pang F; Veale DJ; Bresnihan B; FitzGerald O
Rheumatology (Oxford); 2007 Jul; 46(7):1148-52. PubMed ID: 17478471
[TBL] [Abstract][Full Text] [Related]
16. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
Torrance GW; Tugwell P; Amorosi S; Chartash E; Sengupta N
Rheumatology (Oxford); 2004 Jun; 43(6):712-8. PubMed ID: 15039494
[TBL] [Abstract][Full Text] [Related]
17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
18. [Quality of life of patients with rheumatoid arthritis undergoing out-patient treatment with TNF inhibitors].
Fernández Lisón LC; Vázquez Domínguez B; Luis Fernández J; Moreno Alvarez P; Fruns Giménez I; Liso Rubio J
Farm Hosp; 2008; 32(3):178-81. PubMed ID: 18840348
[TBL] [Abstract][Full Text] [Related]
19. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
Chen JS; Makovey J; Lassere M; Buchbinder R; March LM
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]